샘플 요청 목록

 카트 문의
시장보고서
상품코드
1752998

에볼라 출혈열 치료제 및 백신 시장

Ebola Drugs and Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 485 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

에볼라 출혈열 치료제 및 백신 세계 시장은 2030년까지 1억 4,550만 달러에 이를 전망

2024년에 3,620만 달러로 추정되는 에볼라 출혈열 치료제 및 백신 세계 시장은 2024-2030년 CAGR 26.1%로 성장하여 2030년에는 1억 4,550만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 ZMapp는 CAGR23.6%를 나타내고, 분석 기간 종료시에는 4,700만 달러에 이를 것으로 예측됩니다. Favipiravir 부문의 성장률은 분석 기간중 CAGR 25.9%로 추정됩니다.

미국 시장은 990만 달러로 추정, 중국은 CAGR 34.0%를 보일 것으로 예측

미국의 에볼라 출혈열 치료제 및 백신 시장은 2024년에 990만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 34.0%로 성장을 지속하여 2030년까지 3,510만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 21.3%와 23.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 21.9%로 추정됩니다.

세계의 에볼라 출혈열 치료제 및 백신 시장 - 주요 동향과 촉진요인 정리

에볼라 치료제 및 백신이 향후 전염병 발생 및 세계 보건 위기 예방에 필수적인 이유는 무엇일까?

에볼라 출혈열 치료제 및 백신은 세계에서 가장 위험하고 치사율이 높은 바이러스성 질병에 대한 세계 대응 전략의 핵심입니다. 에볼라 바이러스는 출혈열을 유발하고 사망률이 50% 이상의 것으로 알려져 있으며, 특히 의료 인프라가 취약한 지역에서 공중보건에 심각한 위협이 되고 있습니다. 역사적으로 에볼라 전염병은 중앙아프리카와 서아프리카에 국한되어 있었지만, 전 세계 여행과 무역의 상호 연결로 인해 국경 간 감염의 위험이 증가함에 따라 효과적인 치료제 및 백신의 개발 및 보급이 국제적으로 시급한 과제로 대두되고 있습니다. 2014년부터 2016년까지 서아프리카에서 발생한 에볼라 바이러스는 강력한 의료 대책의 필요성을 강조하고, 에볼라 치료제 및 백신 연구개발과 승인을 가속화하기 위한 전 세계적인 노력을 촉발하는 계기가 되었습니다. 이후 인마제브, 에반가 등 단클론 항체 및 엘베보와 같은 백신은 에볼라 발병을 관리하기 위한 최전방 도구로 등장하여 생존율을 획기적으로 개선하고 보다 효과적인 봉쇄를 가능하게 했습니다. 이러한 도구는 생명을 구할 뿐만 아니라 감염을 줄이고, 일선 의료진을 보호하고, 전염병 비상사태에 대한 사회적 신뢰를 회복하는 데에도 도움이 되고 있습니다. 에볼라출혈열이 반복되는 인수공통전염병의 위협에 직면한 지금, 미래의 건강 위기를 예방하고 전염병에 대한 대비를 유지하기 위해서는 의약품과 백신에 대한 지속적인 투자가 필수적입니다.

과학의 발전과 긴급 대응 프레임워크가 에볼라 치료제의 혁신을 어떻게 촉진하고 있는가?

에볼라 치료제 및 백신 개발 상황은 최첨단 과학 혁신, 세계 협력, 그리고 긴급 상황에 대응하기 위해 구축된 민관 파트너십에 힘입어 빠르게 발전하고 있습니다. 초기에는 에볼라 출혈열의 산발적이고 지리적으로 제한된 유행이 걸림돌이 되었지만, 서아프리카에서 발병한 후 연구개발 노력은 전례 없는 추진력을 얻었고, 임상시험의 가속화와 긴급 사용 승인으로 이어졌습니다. 인마제브(3종의 항체 칵테일)와 에반가(단일 항체)와 같은 단클론 항체 치료는 임상 현장에서 바이러스를 무력화시키고 생존율을 향상시키는 놀라운 효과를 보여주었습니다. 백신 측면에서는 재조합형 수포성구내염 바이러스 기반의 Ervebo 백신이 1회 접종으로 예방 효과를 발휘하여 콩고민주공화국에서 발생한 발병 시 링백신 접종 전략에 성공적으로 도입되었습니다. 아데노바이러스 벡터와 mRNA 플랫폼을 이용한 신규 백신 후보물질도 개발 중이며, 코로나19 백신 개발의 교훈을 바탕으로 보다 신속한 제조와 광범위한 방어가 가능하도록 하고 있습니다. 또한, 실시간 유전체 감시 및 모바일 진단 플랫폼은 보다 타겟팅된 치료 접근법과 신속한 발병 파악을 가능하게 하고 있으며, WHO, CEPI, GAVI와 같은 조직은 세계 대응 프레임워크 조정, 백신 비축 촉진, 개발 촉진 자금 지원 등에서 매우 중요한 역할을 하고 있습니다. 이러한 진전은 에볼라 퇴치에 있어 지속적인 과학적 혁신, 유연한 규제 체계, 협력적 대응 전략의 중요성을 강조하고 있습니다.

왜 지리적, 경제적, 인프라적 요인이 에볼라 치료제 및 백신 배포에 영향을 미치는가?

에볼라 치료제 및 백신의 배포는 해당 지역의 보건 인프라, 경제력, 물류 준비에 따라 크게 좌우됩니다. 콩고민주공화국, 기니, 우간다와 같은 국가들은 여러 차례의 대유행을 경험했으며, 긴급 대응을 위해 국제 원조와 보건 파트너십에 크게 의존하고 있습니다. 이들 지역에서는 취약한 보건 시스템, 제한된 콜드체인 역량, 외딴 지역 주민, 정치적 불안 등으로 인해 신속한 구호 활동의 제공과 시행이 종종 복잡해집니다. 승인된 백신과 치료법이 있음에도 불구하고, 잘못된 정보, 백신 접종에 대한 거부감, 문화적 저항, 불충분한 감시 등의 문제로 인해 백신 접종과 효과에 장애가 되고 있습니다. 반면, 고소득 국가들은 필요한 경우 신속하게 대응할 수 있는 기술력과 보건 인프라를 갖추고 있지만, 위험도가 낮기 때문에 에볼라에 특화된 자원을 우선순위에 두지 않는 경우가 많습니다. 따라서 이러한 격차를 해소하기 위해서는 백신의 형평성을 높이는 COVAX와 같은 노력과 현지 생산 및 유통을 늘리기 위한 지역 제조 파트너십을 통한 국제협력이 필수적입니다. 또한, 현지 의료진 훈련, 질병 감시 네트워크 강화, 지역 사회 참여에 대한 투자는 효과적인 배포에 필수적인 요소입니다. 이러한 지역적 뉘앙스의 차이는 의료 기술 혁신만으로는 충분하지 않으며, 물류 조정, 사회 및 정치 전략, 의료 시스템 강화가 에볼라 치료제 및 백신의 성공적인 공급과 활용을 위해 똑같이 중요하다는 것을 보여줍니다.

에볼라 치료제 및 백신 시장의 성장을 가속하는 주요 요인은?

에볼라 치료제 및 백신 시장의 성장은 반복적인 발병, 세계 보건 안보의 우선순위 증가, 정부 및 국제 보건기구의 전략적 자금 지원의 조합에 의해 이루어지고 있습니다. 야생동물에 에볼라 바이러스의 저수지가 존재하고 동물에서 사람으로의 감염이 빈번하게 발생함에 따라 지속적인 경계와 대비가 필요함을 강조하고 있습니다. 이러한 긴급성은 미국 바이오메디컬첨단연구개발국(BARDA), 전염병대응혁신연합(CEPI), 세계보건기구(WHO)와 같은 기관들의 지속적인 연구개발 투자로 이어지고 있으며, 이들 기관들은 에볼라 치료제 및 백신의 개발, 조달, 배포에 적극적으로 자금을 지원하고 있습니다. 자금을 제공합니다. 이 시장은 항체 치료제와 벡터 기반 백신의 확장 가능한 생산을 가능하게 하는 생물학적 제제 제조의 발전으로 인해 더욱 촉진되고 있습니다. 또한, 코로나19 팬데믹은 강력한 백신 플랫폼과 팬데믹 대비의 필요성에 대한 세계 인식을 높이고, 신속한 개발 및 집단 예방접종 전략의 성공을 보여줌으로써 간접적으로 에볼라 대응 파이프라인에 도움이 되고 있습니다. 또한, 전략적 비축 프로그램과 국제 원조 패키지는 특히 고위험 지역에서 에볼라 개입에 대한 기본적인 수요를 보장하고 있습니다. 제약사들은 반복적인 수요 발생 가능성을 인식하고 신속한 대응 제조 및 규제적 민첩성을 위한 역량을 확대하고 있습니다. 이러한 요인들이 결합되어 보다 탄력적이고, 대응력이 있으며, 상업적으로 실행 가능한 에볼라 치료제 및 백신 시장이 형성되고 있습니다.

부문

신약 유형(ZMapp, Favipiravir, Gs-5734, Tkm-Ebola, Avi-7537);백신 유형(Cad3-Zebov, Rvsv-Zebov,기타 백신 유형);균주 유형(Zaire, Sudan, Tai Forest, Reston, Bundibugyo Virus);최종사용자(병원＆클리닉, 외래수술센터(ASC), 기타 최종사용자)

조사 대상 기업 예(총 44개사)

  • AIM ImmunoTech
  • Arbutus Biopharma Corporation
  • Bavarian Nordic A/S
  • BioCryst Pharmaceuticals, Inc.
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Fujifilm Toyama Chemical Co., Ltd.
  • GeneOne Life Sciences, Inc.
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • IMV Inc.
  • Johnson & Johnson
  • Mapp Biopharmaceutical, Inc.
  • NanoViricides, Inc.
  • NewLink Genetics Corporation
  • Novavax, Inc.
  • Peptineo LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.26

Global Ebola Drugs and Vaccines Market to Reach US$145.5 Million by 2030

The global market for Ebola Drugs and Vaccines estimated at US$36.2 Million in the year 2024, is expected to reach US$145.5 Million by 2030, growing at a CAGR of 26.1% over the analysis period 2024-2030. ZMapp, one of the segments analyzed in the report, is expected to record a 23.6% CAGR and reach US$47.0 Million by the end of the analysis period. Growth in the Favipiravir segment is estimated at 25.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.9 Million While China is Forecast to Grow at 34.0% CAGR

The Ebola Drugs and Vaccines market in the U.S. is estimated at US$9.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.1 Million by the year 2030 trailing a CAGR of 34.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.3% and 23.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.9% CAGR.

Global Ebola Drugs and Vaccines Market - Key Trends & Drivers Summarized

Why Are Ebola Drugs and Vaccines Vital in Preventing Future Outbreaks and Global Health Crises?

Ebola drugs and vaccines are central to the global response strategy against one of the world’s most dangerous and highly fatal viral diseases. The Ebola virus, known for causing hemorrhagic fever and having mortality rates that can exceed 50%, poses a serious threat to public health, especially in regions with fragile healthcare infrastructure. While outbreaks have historically been confined to Central and West Africa, the interconnectedness of global travel and trade elevates the risk of cross-border transmission, making the development and deployment of effective therapeutics and vaccines a matter of international urgency. The unprecedented 2014-2016 West African outbreak, which claimed over 11,000 lives, underscored the dire need for robust medical countermeasures and catalyzed major global efforts to accelerate research, development, and approval of Ebola-specific drugs and vaccines. Treatments like monoclonal antibodies (e.g., Inmazeb and Ebanga) and vaccines such as Ervebo have since emerged as frontline tools in managing outbreaks, drastically improving survival rates and enabling more effective containment. These tools are not only life-saving but also instrumental in reducing transmission, protecting frontline health workers, and restoring public confidence during epidemic emergencies. With Ebola now considered a recurring zoonotic threat, sustained investment in drugs and vaccines is essential to prevent future health crises and maintain epidemic preparedness.

How Are Scientific Advancements and Emergency Response Frameworks Driving Innovation in Ebola Therapeutics?

The Ebola drug and vaccine landscape has rapidly evolved, propelled by cutting-edge scientific innovation, global collaboration, and public-private partnerships forged in response to outbreak emergencies. Initially hindered by the sporadic and geographically limited nature of Ebola outbreaks, R&D efforts gained unprecedented momentum following the West African epidemic, leading to accelerated clinical trials and emergency use authorizations. Monoclonal antibody treatments such as Inmazeb (a cocktail of three antibodies) and Ebanga (a single antibody) have demonstrated significant efficacy in neutralizing the virus and improving survival in clinical settings. On the vaccine front, the recombinant vesicular stomatitis virus-based Ervebo vaccine has been a game-changer, providing single-dose protection and being successfully deployed in ring vaccination strategies during outbreaks in the Democratic Republic of Congo. Novel vaccine candidates using adenovirus vectors and mRNA platforms are also under development, drawing on lessons from COVID-19 vaccine development to enable faster production and broader protection. Additionally, real-time genomic surveillance and mobile diagnostic platforms are enabling more targeted therapeutic approaches and quicker outbreak identification. Organizations such as the WHO, CEPI, and GAVI play pivotal roles in coordinating global response frameworks, facilitating vaccine stockpiling, and funding accelerated development efforts. These advancements underscore the importance of sustained scientific innovation, flexible regulatory mechanisms, and coordinated response strategies in the fight against Ebola.

Why Do Geographic, Economic, and Infrastructural Factors Influence Ebola Drug and Vaccine Deployment?

The deployment of Ebola drugs and vaccines is profoundly shaped by regional health infrastructure, economic capacity, and logistical readiness, with sub-Saharan Africa remaining the epicenter of disease burden and intervention efforts. Countries such as the Democratic Republic of Congo, Guinea, and Uganda have experienced multiple outbreaks and rely heavily on international aid and health partnerships for emergency response. In these areas, fragile health systems, limited cold chain capabilities, remote populations, and political instability often complicate rapid delivery and administration of life-saving interventions. Despite the availability of approved vaccines and treatments, challenges such as misinformation, vaccine hesitancy, cultural resistance, and inadequate surveillance can hinder uptake and effectiveness. In contrast, high-income countries possess the technological capacity and health infrastructure to deploy countermeasures rapidly if needed, but often deprioritize Ebola-specific resources due to lower risk profiles. International cooperation is therefore essential to bridge these disparities-through initiatives such as COVAX for vaccine equity and regional manufacturing partnerships aimed at increasing local production and distribution. Moreover, training local healthcare workers, strengthening disease monitoring networks, and investing in community engagement are vital components of effective deployment. These regional nuances demonstrate that medical innovation alone is insufficient-logistical coordination, socio-political strategy, and health system strengthening are equally critical in ensuring successful delivery and utilization of Ebola drugs and vaccines.

What Are the Key Drivers Fueling Growth in the Ebola Drugs and Vaccines Market?

The growth in the Ebola drugs and vaccines market is driven by a combination of recurring outbreaks, heightened global health security priorities, and strategic funding from governments and international health bodies. The persistence of Ebola virus reservoirs in wildlife and the increasing frequency of spillover events from animals to humans highlight the need for continuous vigilance and preparedness. This urgency has translated into sustained investment in R&D from organizations such as the U.S. Biomedical Advanced Research and Development Authority (BARDA), the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), all of which are actively funding the development, procurement, and distribution of Ebola therapeutics and vaccines. The market is further propelled by advancements in biologics manufacturing, enabling scalable production of antibody therapies and vector-based vaccines. The COVID-19 pandemic has also increased global awareness about the necessity of robust vaccine platforms and pandemic readiness, indirectly benefiting the Ebola countermeasures pipeline by showcasing the success of rapid development and mass immunization strategies. Additionally, strategic stockpiling programs and international aid packages ensure a baseline demand for Ebola interventions, particularly in at-risk regions. Pharmaceutical companies, recognizing the potential for recurring demand, are expanding capabilities for rapid response manufacturing and regulatory agility. Together, these factors are driving a more resilient, responsive, and commercially viable market for Ebola drugs and vaccines-one that is increasingly aligned with the broader goal of global health security.

SCOPE OF STUDY:

The report analyzes the Ebola Drugs and Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Novel Drug Type (ZMapp, Favipiravir, Gs-5734, Tkm-Ebola, Avi-7537); Vaccine Type (Cad3-Zebov, Rvsv-Zebov, Other Vaccine Types); Strain Type (Zaire, Sudan, Tai Forest, Reston, Bundibugyo Virus); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AIM ImmunoTech
  • Arbutus Biopharma Corporation
  • Bavarian Nordic A/S
  • BioCryst Pharmaceuticals, Inc.
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Fujifilm Toyama Chemical Co., Ltd.
  • GeneOne Life Sciences, Inc.
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • IMV Inc.
  • Johnson & Johnson
  • Mapp Biopharmaceutical, Inc.
  • NanoViricides, Inc.
  • NewLink Genetics Corporation
  • Novavax, Inc.
  • Peptineo LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Ebola Drugs and Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Health Security Agendas Throw the Spotlight on Ebola Drug and Vaccine Development
    • Recurrent Outbreaks in Central and West Africa Propel Demand for Rapid Deployment Therapeutics
    • Here's How Emergency Use Authorizations Accelerate Market Entry of Experimental Ebola Solutions
    • WHO Prequalification of Ebola Vaccines Strengthens Procurement by Global Health Bodies
    • Growth in Zoonotic Surveillance Expands Addressable Market for Preventive and Post-Exposure Solutions
    • Here's the Story: Multilateral Funding and NGO Partnerships Fuel Access in Resource-Constrained Areas
    • Innovations in Viral Vector and RNA Vaccine Platforms Enhance Rapid Response Capability
    • Cold-Chain Optimization Initiatives Improve Last-Mile Delivery of Thermally Sensitive Vaccines
    • Dual-Use Vaccine Development Models Create Synergies With Other Hemorrhagic Fever Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ebola Drugs and Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ebola Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for ZMapp by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for ZMapp by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for ZMapp by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Favipiravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Favipiravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Favipiravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gs-5734 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gs-5734 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Gs-5734 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tkm-Ebola by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tkm-Ebola by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Tkm-Ebola by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Avi-7537 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Avi-7537 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Avi-7537 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sudan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sudan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Sudan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tai Forest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tai Forest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Tai Forest by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Reston by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Reston by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Reston by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Bundibugyo Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Bundibugyo Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Bundibugyo Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Zaire by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Zaire by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Zaire by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Cad3-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Cad3-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Cad3-Zebov by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Rvsv-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Rvsv-Zebov by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Rvsv-Zebov by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • CHINA
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Ebola Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • INDIA
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Ebola Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Ebola Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Ebola Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Ebola Drugs and Vaccines by Novel Drug Type - ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Novel Drug Type - Percentage Breakdown of Value Sales for ZMapp, Favipiravir, Gs-5734, Tkm-Ebola and Avi-7537 for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Ebola Drugs and Vaccines by Strain Type - Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Strain Type - Percentage Breakdown of Value Sales for Sudan, Tai Forest, Reston, Bundibugyo Virus and Zaire for the Years 2015, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Ebola Drugs and Vaccines by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Ebola Drugs and Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Ebola Drugs and Vaccines by Vaccine Type - Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Ebola Drugs and Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Cad3-Zebov, Rvsv-Zebov and Other Vaccine Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제